Abciximab is considered which type of drug?

Abciximab is classified as a chimeric monoclonal antibody, which means it is a type of therapeutic agent designed to target specific receptors in the body. In the case of abciximab, it specifically inhibits the glycoprotein IIb/IIIa receptor on platelets, which plays a crucial role in the aggregation and activation of platelets during the clotting process.

This targeted action allows abciximab to effectively reduce the risk of thrombotic events, especially in patients undergoing percutaneous coronary interventions. The chimeric nature of the antibody means that it is constructed from both human and mouse components, which enhances its efficacy while minimizing the risk of immunogenicity compared to fully murine antibodies.

By understanding that abciximab is a chimeric monoclonal antibody, one can appreciate its specificity and mode of action in the context of antiplatelet therapy, making it a vital option in the management of patients at high risk for thrombotic complications.